Short bowel syndrome often occurs in people whose small intestine has been surgically removed in half or more, leaving the remaining length of intestine no more than 120cm, associated with poor absorption of nutrients.

An important goal when treating patients with short bowel syndrome (short bowel syndrome) requiring parenteral nutrition or fluid support is to reduce dependence on this support and completely eliminate the use of these drugs. whenever possible.

Teduglutide, a recombinant, anti-aging, longer-acting GLP-2 analog, was shown in an open-label study to be safe, well tolerated, intestinal stimulant, and significantly increased absorption. Wet weight of the intestine, but no energy absorption in 16 short bowel syndrome patients with jejunostomy or colostomy.